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Common BACE2 Polymorphisms 
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for Alzheimer’s Disease and CSF 
Amyloid Biomarkers in APOE ε4 
Non-Carriers
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It was recently suggested that beta-site amyloid precursor protein (APP)-cleaving enzyme 2 (BACE2) 
functions as an amyloid beta (Aβ)-degrading enzyme; in addition to its better understood role as an 
APP secretase. Due to this finding we sought to understand the possible genetic risk contributed by 
the BACE2 locus to the development of late-onset Alzheimer’s disease (AD). In this study, we report 
that common single nucleotide polymorphism (SNP) variation in BACE2 is associated with altered AD 
risk in apolipoprotein E gene (APOE) epsilon 4 variant (ε4) non-carriers. In addition, in ε4 non-carriers 
diagnosed with AD or mild cognitive impairment (MCI), SNPs within the BACE2 locus are associated 
with cerebrospinal fluid (CSF) levels of Aβ1-42. Further, SNP variants in BACE2 are also associated with 
BACE2 RNA expression levels suggesting a potential mechanism for the CSF Aβ1-42 findings. Lastly, 
overexpression of BACE2 in vitro resulted in decreased Aβ1-40 and Aβ1-42 fragments in a cell line model 
of Aβ production. These findings suggest that genetic variation at the BACE2 locus modifies AD risk for 
those individuals who don’t carry the ε4 variant of APOE. Further, our data indicate that the biological 
mechanism associated with this altered risk is linked to amyloid generation or clearance possibly 
through BACE2 expression changes.
The amyloid (Aβ) hypothesis of Alzheimer’s disease (AD) has primarily been driven by the observation that 
genetic variability that alters amyloid precursor protein (APP) metabolism increases de position of Aβ1. 
Classically, the causative mutations were in APP itself and in the presenilin genes – PSEN1 and 2. Aβ is generated 
by the sequential actions of β-secretase (BACE1) and γ-secretase, of which the presenilins are the major compo-
nent2. More recently, reduced function variants of both ADAM103 and ADAM174, the enzymes involved in the 
alternate α-secretase cleavage of APP, have been shown to increase the risk of AD as well. Finally, it is clear that 
the homologue of BACE1, BACE2 can also cleave both APP and amyloid beta (Aβ)5,6.
The actions of BACE2 may be involved in altering pathogenic Aβ fragment concentrations in multiple ways. It 
is known that BACE2 can cleave APP at the β-secretase site (albeit with much lower efficiency than BACE1) and 
near the α-secretase site as well7–9. Fluhrer et al. demonstrated that the cleavage of APP via BACE2 results in pro-
duction of soluble APP-α and reduced production of amyloidogenic species suggesting that APP metabolism by 
BACE2 acts in an opposing fashion to BACE1 in cells that express both enzymes8. However, more recent research 
suggests that the primary activity of BACE2 occurs at a “θ-secretase” site (Phe10) located within the Aβ domain 
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in APP. In 2006, Sun et al. identified this novel θ-secretase site and demonstrated that it results in the prevention 
of Aβ production5. Lastly, Abdul-Hay et al. demonstrated that BACE2 can degrade Aβ with an efficiency second 
only to insulin degrading enzyme (IDE)6.
Although two studies, one in the Finnish population11 and one in Down syndrome, have both implicated 
BACE2 in disease, to date neither exome sequencing or genome-wide association studies have reported common 
or rare pathogenic variability in either BACE1 or BACE2 as altering risk for disease. However, Wang et al. recently 
reported that mutations in the juxtamembrane helix (JH) domain of BACE2 results in a “conditional” β-secretase 
activity that leads to elevated Aβ production thereby establishing a potential genetic basis for BACE2 variation 
in AD risk12.
With this in mind we examined the BACE2 locus, using a clinically characterized and neuropathology con-
firmed sample set (TGenII) as our starting point. We have previously shown that these confirmed samples 
increase the power to detect genetic associations. This is presumably because they avoid the misclassification 
of controls and the misdiagnosis of cases13. Next, we attempted to replicate findings in the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) cohort by examining the cerebrospinal fluid (CSF) biomarker data. Additionally, 
we examined the BACE2 locus for an expression quantitative trait (eQTL) to determine if variants in the region 
could be associated with BACE2 expression levels. Lastly, we confirmed that alteration of BACE2 expression 
influenced Aβ levels in vitro.
Methods
“TGenII” clinically characterized and neuropathologically verified cohort. Subjects from the 
TGenII neuropath cohort were collected as previously described14. We selected cases and controls as subjects of 
European ancestry who were verified pathologically as having AD or not, respectively. Subjects were greater than 
age 65 at death. Board-certified neuropathologists performed Braak staging based on the degree of neurofibrillary 
tangles15, and/or CERAD16 classification on the extent of neuritic plaques. Any samples with a history of other 
known neurological disease and or clinical history of stroke, cerebrovascular disease, and/or Lewy bodies were 
excluded.
ADNI subjects. Subjects from the ADNI cohort (adni.loni.usc.edu) were collected as described previously17. 
Study participants were given both clinical and cognitive assessments. The mini-mental state exam (MMSE)18 was 
used to screen for and score cognitive impairment along with the clinical dementia rating (CDR)19 to determine 
level of dementia. AD subjects were determined as clinically according to the National Institute of Neurological 
and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association 
(NINCDS-ADRDA) criteria20 and having MMSE scores between 20–26 and CDR between 0.5 and 1.0. Mild cogni-
tive impairment (MCI) subjects had MMSE scores between 24–30, CDR = 0.5, reported memory complaints but no 
other signs of impairment of other cognitive functions, and were non-demented. Healthy normal controls (NC) had 
MMSE of 24–30, CDR = 0, and showed no signs of dementia. The primary goal of ADNI has been to test whether 
serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clin-
ical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment 
(MCI) and early Alzheimer’s disease (AD). For up-to-date information, see www.adni-info.org.
Single nucleotide polymorphism (SNP) genotyping. The TGenII cohort was genotyped on the 
Affymetrix Genome-Wide Human SNP 6.0 Array (Affymetrix, Inc., Santa Clara, CA, USA) with standard man-
ufacturer’s protocols (Affymetrix Genome-Wide Human SNP Nsp/Sty 6.0 User Guide; Rev. 1, 2007). The ADNI 
cohort was genotyped on the Illumina Human610-Quad BeadChip (Illumina, Inc. San Diego, CA) according to 
the manufacturer’s protocols (Infinium HD Assay; Super Protocol Guide; Rev. A, May 2008). Both SNP data-
sets are free and publicly available either via the main study sites or through the Alzheimer’s Disease Genetic 
Consortium (ADGC or https://www.nigads.org/datasets/ng00028).
BACE2 locus imputation. Imputation was conducted with IMPUTE2 software (v2.1.2) using the 
multi-population reference panel approach10,21. We used the June 2011 release of the 1000 Genomes 
(1000genomes.org) Phase 1. We imputed a 5 megabase region encompassing BACE2 on chromosome 21 between 
positions 40,000,000-45,000,000 in hg19 coordinates. For the phasing stage we used 80 haplotypes (-k option) as a 
template. For both the phasing and imputation rounds of IMPUTE2, we performed 10 burn in iterations (-burnin 
option) and performed 30 Markov chain Monte Carlo (MCMC) iterations (-iter option). Since we performed the 
multi-population approach, we set the “effective size” option (-Ne) to the suggested value of 20000. In addition, 
we utilized the strand alignment procedure (-fix_strand_g option) to minimize genotype strand discrepancies 
between the reference and study panels. GTOOL was used to convert IMPUTE2 GEN output to PED format.
SNP and haplotype association testing. SNPs with minor allele frequencies less than 1% or with gen-
otyping rate below 95% were filtered prior to analysis. For the initial hypothesis testing of BACE1 and BACE2 a 
Fisher’s exact test was utilized and 1000 max(T) permutations in PLINK22 were performed. After determining 
BACE2 warranted further follow-up, we assessed population structure and incorporated the results as covariates 
in regression models. We used ADMIXTURE23 (v1.04) with K = 3 by selecting a subset of directly genotyped 
SNPs (i.e., not imputed) with >99% call rates, minor allele frequency >0.3, pairwise R2 < 0.01. Q1 and Q2 vec-
tor solutions and sex were included as covariates in the regressions, and APOE ε4 carrier status was included as 
a covariate and genotype interaction term. Haplotypes were called with PLINK using the default parameters. 
Correction for multiple testing during SNP analysis was conducted using the Bonferroni method with independ-
ent SNPs considered to be those with r2 < 0.80.
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Aβ CSF measures. Aβ CSF levels were used from the ADNI dataset. The approach for CSF collection and 
measurement of the Aβ biomarker was reported previously17. The approach for testing Aβ1-42 fragment associa-
tion with BACE2 was carried out in a similar fashion to the AD association; however, instead of using case/control 
as binary phenotypes, we performed a linear regression with Aβ1-42 levels as the phenotype. The imputed BACE2 
SNPs were tested against Aβ1-42 CSF measures with sex and ADMIXTURE K = 3 Q1 and Q2 values as covariates.
In vitro Aβ ELISA measurements. BACE2 overexpression was achieved using the Sleeping Beauty 
Transposon system24. BE(2)-m17 neuroblastoma cells were plated in uncoated, 6-well plates (14e6 cells/well) and 
media exchanged every 24 hours. Seventy-two-hours after plating-, supernatant was collected and supplemented 
with 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) to a final concentration of 1.0 mM. 
Samples were clarified, decanted, and stored at −80 °C until analysis. Extracellular Aβ levels were quantified 
using the Human βAmyloid [1–40] (ThermoFisher Scientific) and the Human Aβ [1-42] ELISAs (ThermoFisher 
Scientific), according to the manufacturer’s instructions.
Highlights. 
•	 SNPs within the BACE2 locus were associated with altered Alzheimer’s disease risk preferentially in APOE 
ε4 non-carriers.
•	 In individuals with diagnosed AD or MCI who do not carry an APOE ε4 allele, SNPs within BACE2 were 
associated with differential Aβ1-42 levels in the CSF.
Figure 1. AD risk is associated with SNPs within the BACE2 locus in APOE ε4 non-carriers. BACE2 
association in the clinically characterized and neuropathologically verified cohort. In all panels, SNP 
uncorrected P-values are plotted as colored circles based on their location within the genetic locus, the size of 
the circle is representative of the CADD score for the SNP. A horizontal red dashed line represents nominal 
significance of p = 0.05. (Top panel) BACE2 association in all discovery subjects (N = 1599; 1014 cases; 585 
controls). (Middle) BACE2 interaction p-values with APOE carrier status (Bottom) BACE2 interaction p-values 
with APOE carrier status including the first two population structure vectors and sex.
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•	 SNPs within BACE2 are associated with BACE2 mRNA levels in control individuals via eQTL analysis and 
this effect is modified by APOE status.
•	 Overexpression of BACE2 in a cell line that naturally produces Aβ peptides results in lower amounts of Aβ1-
40 and Aβ1-42.
•	 Considered together, these data suggest that genetic variation at the BACE2 locus is associated with AD risk 
and that it may be functionally linked to altered Aβ processing.
Results and Discussion
We initiated our study in a cohort of clinically characterized and neuropathologically verified AD cases and 
controls (n = 1599; 1014 cases, 585 controls) known as “TGenII”. This cohort is advantageous for genetic study 
over living, clinically diagnosed AD cohorts due to the absence of the mis-assignment of cases and controls. 
We examined the BACE2 locus in three steps. First, we examined the association at the locus using a simple 
logistic regression case:control analysis examining genotyped and imputed SNPs (Fig. 1, top panel). The SNP 
rs8134992 was identified as the most significant with an uncorrected p-value of 0.00136. Next, we examined 
this association after including APOE carrier status (e.g. 0, 1, or 2 APOE ε4 alleles) as an interaction term in 
the additive logistic regression model (Fig. 1, middle panel). This yielded a significant association at rs2898441 
with an uncorrected p-value of 0.0267. In a final analysis of this association we included the first two population 
structure co-variates and sex as interaction terms in addition to APOE carrier status (Fig. 1, bottom panel). This 
resulted in rs9978431 as the SNP with the most significant p-value at 0.0249. All of the data for these comparisons 
can be found in Supplemental Tables 1–3. The interaction with APOE status was further analyzed by performing 
Figure 2. CSF Aβ1-42 levels are associated with BACE2 locus SNPs in AD and MCI Individuals from the ADNI 
cohort who are APOE ε4 non-carriers. BACE2 association with Aβ1-42 CSF levels in ADNI cohort AD, MCI, 
and control NA individuals including APOE carrier status, the first two population structure vectors, and sex as 
interaction terms. In all panels, uncorrected SNP P-values are plotted as colored circles based on their location 
within the genetic locus, the size of the circle is representative of the CADD score for the SNP. A horizontal 
red dashed line represents nominal significance of p = 0.05. (Top panel) BACE2 interaction p-values in ADNI 
AD individuals. (Middle) BACE2 interaction p-values in ADNI MCI individuals. (Bottom) BACE2 interaction 
p-values in ADNI control NA individuals.
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a post-hoc examination of the association signal across the locus by splitting the cohort into APOE carriers 
and non-carriers. This demonstrated that the association within BACE2 was only significant in the APOE ε4 
non-carriers (Supplemental Fig. 1). In an attempt to relate potential functional impact to the SNPs we utilized 
CADD scoring25. There were no SNPs with CADD scores over 15 suggesting that the associated SNPs do not have 
direct impact at the protein function level.
These association results, in a well characterized neuropathology-confirmed cohort, suggest that there are 
common SNPs within the BACE2 locus that alter AD risk preferentially in individuals who do not carry the 
APOE ε4 genetic risk for the disease. This is important to note due to the role of BACE2 in amyloid processing. 
Due to this finding, we next hypothesized that genetic variation at BACE2 would be associated with Aβ1-42 bio-
marker levels due to its ability to degrade the peptide or via its theta-secretase actions which could lead to lowered 
Aβ1-42 production by shunting APP metabolism down a non-amyloidogenic path.
Using the ADNI cohort and a linear regression analysis incorporating the first two population structure 
co-variates, sex, and APOE carrier status as interaction terms, we demonstrated an association with CSF Aβ 1-42 
levels that was significant in the MCI and AD individuals (Fig. 2). The strongest associated SNPs (rs2837994 in 
AD at p = 0.000183 and rs9980146 in MCI at p = 0.0207, both uncorrected) were located in the same region as 
defined above for the BACE2 genetic association. Of note, there was no significant association in the NA control 
individuals in ADNI suggesting that this locus may be preferentially relevant for CSF Aβ1-42 biomarker levels 
during disease processes. As before, we utilized a post-hoc analysis to identify which APOE group was associated 
with the CSF Aβ1-42 changes and found that the association was again only significant in APOE ε4 non-carriers. 
This is in agreement with the genetic associations we detected in the first phase of our study. The full results of this 
analysis can be found in Supplemental Tables 4–6.
Figure 3. BACE2 locus SNPs are associated with BACE2 gene expression levels in cortex samples from control 
donors. eQTL p-values are indicated for BACE2 SNPs across three different array probes for BACE2 expression. 
In all panels, uncorrected SNP P-values are plotted as colored circles based on their location within the genetic 
locus, the size of the circle is representative of the CADD score for the SNP. A horizontal red dashed line 
represents nominal significance of p = 0.05. (Top panel) BACE2 eQTL p-values in control individuals for probe 
GI21040361-A. (Middle) BACE2 eQTL p-values in control individuals for probe ILMN1669323. (Bottom) 
BACE2 eQTL p-values in control individuals for probe ILMN2326712.
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The work in the ADNI cohort further supports the association at the BACE2 locus and its specificity in APOE 
ε4 non-carriers. No variants identified during the CADD scoring approach clearly have the potential to alter 
protein function. To that end, we predicted that BACE2 gene expression levels may be altered by the associated 
variants; thus, in turn, altered levels of BACE2 mRNA and protein would lead to an alteration in Aβ1-42.
To examine this we utilized an expression quantitative trait locus (eQTL) analysis approach to identify var-
iants within the BACE2 locus that may be associated with BACE2 RNA levels. We utilized array-based gene 
expression data from the TGenII cohort cortical brain tissue samples from control individuals only (to avoid any 
confounding influence of disease on gene expression). Three probes that are specific to BACE2 were examined 
and all three demonstrated an eQTL association that was modified by APOE carrier status (Fig. 3). Of particular 
note was SNP rs2012050 (p = 0.0425, uncorrected) which was also identified as significant in the ADNI MCI 
cohort CSF Aβ1-42 analysis. APOE ε4 non-carriers of the minor allele of rs2012050 demonstrate lower BACE2 
gene expression and also higher CSF Aβ1-42 levels (Fig. 4). This is in agreement with the potential actions of 
BACE2 on Aβ1-42. All of the eQTL data can be found in Supplemental Tables 7–9.
Next we overexpressed BACE2 in a cell line that we showed previously expresses the necessary genetic compo-
nents and produces Aβ fragments in vitro26. Notably, this cell line expresses BACE2 at very low levels (less than 0.5 
FPKM based on RNA sequencing data, not shown). We overexpressed BACE2 in this cell line and demonstrated that 
Figure 4. SNP rs2012050 is associated with altered BACE2 gene expression and Aβ1-42 CSF levels. The 
relationship between rs2012050 genotype (x-axis) and either Aβ1-42 CSF levels (Top panel) or BACE2 gene 
expression (Bottom) is shown. APOE carrier status is indicated by the color of the boxplot; red = APOE ε4 non-
carriers, blue = APOE ε4 carriers. Note the higher levels of Aβ1-42 in the CSF from rs2012050 T/T individuals 
who are APOE ε4 non-carriers as well as a lower expression of the BACE2 gene in individuals with the same 
genetic characteristics.
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this resulted in lower amounts of Aβ1-40 and 1-42 fragments in the cell culture media (Fig. 5). This final experiment 
confirmed other reports in the literature demonstrating that BACE2 can degrade Aβ peptides6. Further, these data 
suggest that the alteration of BACE2 expression may result in the CSF level alterations we observed.
Collectively, this work supports previous analyses suggesting that genetic variability in BACE2 alters mRNA 
expression and plays a role in AD. Understanding the precise role of BACE2 in APP/Aβ metabolism is clearly 
important because drugs designed as BACE1 inhibitors also demonstrate cross-reactivity with BACE2. The effect 
of BACE2 inhibition on APP processing would likely be anti-amyloidogenic since it would lead to less Aβ being 
formed8, but inhibition of BACE2 may also reduce its cleavage of Aβ. However, it is noteworthy that Sun et al.5 
suggested increasing BACE2 activity was a valid approach for AD therapy given its high propensity to degrade 
Aβ. This suggests that inhibition of BACE2 is not a desirable approach. A further complication, when trying to 
predict the effects of BACE2 inhibition on disease etiology, is that BACE2 expression is high in both neurons and 
glial cells. This means that with the gliosis inherent in the AD disease process, BACE2 expression may become 
more pronounced as the disease progresses. Indeed, it is possible that such a BACE2 effect on pathogenesis dur-
ing AD disease progression may underlie the APOE effect we report herein. Importantly, our data suggest that 
BACE2 has important roles in APP/Aβ metabolism. Indeed, this has wide reaching implications 1) for assess-
ment of BACE inhibition in AD treatment, and 2) in the interpretation of AD rodent models where the Swedish 
(“BACE1 preferring”) mutation is used to model the disease.
Data Availability
All SNP genotypes and CSF biomarker levels are available openly via the respective study sites or through the 
ADGC.
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